Contineum Therapeutics (CTNM)

• Market cap: $579M
• 1 day: -1.65%
• 5 days: 8.47%
• 1 month: -5.49%
• 3 months: 20.83%
• 6 months: 7.72%
• Year to date: 36%
• 1 year: 162.54%
• 5 years: 0.58%
• 10 years: 0.58%
• Sector: Healthcare
• Industry: Biotechnology

About: Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Employees: 51